Anyone with common sense dealing with this sector wouldn't find this new unsettling. This is also the problem (part of) the Warp Speed program. Failing to do their due diligence. Throwing our hard earned money into failure like throwing darts blindfolded trying to hit a double bull.

It just doesn't happen.

Brilacidin may hold SOME potential to make the curve but we need to see the trial that moves us into the competition.

Protocol and peer review. That's where the excitement begins imo.

http://www.ipharminc.com/email-alerts